Paratek Pharmaceuticals, Inc. (PRTK)
After hours:
| Previous Close | 4.5500 |
| Open | 4.5500 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1800 |
| Day's Range | 4.4800 - 4.7000 |
| 52 Week Range | 4.0300 - 11.2400 |
| Volume | |
| Avg. Volume | 312,293 |
| Market Cap | 216.753M |
| Beta (5Y Monthly) | 1.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1850 |
| Earnings Date | Feb. 24, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Oct. 31, 2014 |
| 1y Target Est | 21.75 |
- GlobeNewswire
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on November 30, 2021, the Company granted stock options to ten new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, I
- GlobeNewswire
Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that Evan Loh, chief executive officer, will present at the 2021 Jefferies London Healthcare Conference. The on-demand presentation will be available Thursday, Nov. 18 beginning at 3 a.m. EST through Friday, Nov. 19 at 12 p.m. EST. To access the webcast, please visit: https://wsw.meetmax.com/admin/presenterlinks/?436013913&group=TbkBHEif. A replay of the webcast can be accessed for up to 30 day
- Zacks
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of 22.92% and 6.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
